FDA
-
-
-
-
-
-
-
BTIG Downgrades Aardvark Therapeutics Inc (AARD) to Neutral
-
-
-
-
-
-
-
Stifel Cautious on Aardvark Therapeutics Inc (AARD) Amid 5% drop: 'without more clarity it's hard for us to get comfortable right now with the added uncertainty'
-
-
-
-
-
-
-
RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform
-
-
-
-
-
-
-
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
-
-
-
-
-
-
-
Aardvark Therapeutics Inc (AARD) PT Raised to $26 at BofA Securities
-
330,680 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

